Sloan Sheldon sold $731K of SYRE
Sloan Sheldon (Chief Medical Officer) sold 8,334 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.70 ($87.52–$88.34, $0.73M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale by the Chief Medical Officer (Sloan Sheldon) totaling ~$730.9K at ~$87.70 weighted average, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this filing alone does not introduce new clinical, regulatory, or financial guidance.
What to watch
The article provides no context on total planned sales, prior holdings history, or whether other insiders are selling/buying; without that, signal quality is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics, Inc. (SYRE).
Ticker impact
Form 4 shows CMO Sloan Sheldon sold 8,334 SYRE shares in open-market trades on 2026-07-01 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.
The filing is an SEC Form 4 insider transaction with explicit 10b5-1 pre-arrangement and the CMO ends with 0 shares, but no new company-specific operational or financial information is disclosed.
Market effects
Minimal; this is company-specific insider liquidity rather than a sector-wide regulatory/clinical catalyst.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can still coincide with internal confidence in near-term liquidity needs, so the market may overreact to the headline “insider sold.”
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderSloan Sheldon
Chief Medical Officer who sold 8,334 shares on 2026-07-01 under a 10b5-1 plan.
